Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank17
3Y CAGR-64.0%
5Y CAGR-63.4%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-64.0%/yr
Annual compound
5Y CAGR
-63.4%/yr
Consistent
Percentile
P17
Within normal range
vs 5Y Ago
0x
Contraction
Streak
5 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 3.44% |
| 2024 | 9.78% |
| 2023 | 17.26% |
| 2022 | 73.73% |
| 2021 | 292.68% |
| 2020 | 521.89% |
| 2019 | 0.00% |